

# Erica K Evans

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4114183/publications.pdf>

Version: 2024-02-01

6  
papers

486  
citations

1478505

6  
h-index

1872680

6  
g-index

6  
all docs

6  
docs citations

6  
times ranked

629  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. <i>Nature Medicine</i> , 2021, 27, 2183-2191.	30.7	78
2	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2020, 21, 935-946.	10.7	186
3	Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis. <i>Leukemia</i> , 2019, 33, 1195-1205.	7.2	38
4	Targeting kinases with precision. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1435183.	0.7	15
5	A precision therapy against cancers driven by <i>KIT/PDGFR</i> mutations. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	157
6	Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM). <i>Blood</i> , 2016, 128, 477-477.	1.4	12